Humana Inc. (HUM) P/E Ratio History
Historical price-to-earnings valuation from 1991 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Humana Inc. (HUM) trades at a price-to-earnings ratio of 19.1x, with a stock price of $190.54 and trailing twelve-month earnings per share of $10.69.
The current P/E is roughly in line with its 5-year average of 21.0x. Over the past five years, HUM's P/E has ranged from a low of 14.9x to a high of 28.0x, placing the current valuation at the 35th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, HUM trades at a 19% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, HUM trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HUM DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. National Multi-Line Health Insurers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ELVElevance Health Inc. | $71B | 12.7Lowest | 1.84Best | -2%Best |
HUMHumana Inc. | $23B | 19.1 | - | -50% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $260.17 | $10.67 | 24.4x | +13% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $244.48 | $13.03 | 18.8x | -13% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $264.60 | $14.15 | 18.7x | -13% |
| FY2024 Q4 | $253.71 | $9.96 | 25.5x | +18% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $316.74 | $11.30 | 28.0x | +30% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $373.65 | $14.03 | 26.6x | +23% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $346.72 | $16.06 | 21.6x | -0% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $457.81 | $19.82 | 23.1x | +7% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $486.52 | $24.12 | 20.2x | -7% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $447.13 | $26.80 | 16.7x | -23% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $485.46 | $24.62 | 19.7x | -9% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $512.19 | $22.04 | 23.2x | +8% |
Average P/E for displayed period: 21.6x
See HUM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HUM Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare HUM vs AGIO
See how HUM stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is HUM stock overvalued or undervalued?
HUM trades at 19.1x P/E, near its 5-year average of 21.0x. The 35th percentile ranking places valuation within normal historical bounds.
How does HUM's valuation compare to peers?
Humana Inc. P/E of 19.1x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is HUM's PEG ratio?
HUM PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1991-2025.